Skip to main content

Table 6 Combination of target therapy and immunotherapy

From: The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of

NCT No. Drug 1 Drug2 Conditions Phase region Start year results
NCT03149120 Nivolumab Pazopanib Soft Tissue Sarcomas Phase II US 2017 No
NCT03190174 Nivolumab Rapamycin Undifferentiated Pleomorphic Sarcoma|Liposarcoma|Chondrosarcoma|Osteosarcoma|Ewing Sarcoma Phase I| Phase II US 2017 No
NCT02636725 Pembrolizumab Axitinib Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas Phase II US 2016 No
NCT03359018 Camrelizumab Apatinib osteosarcoma Phase II Asia 2018 No
NCT03277924 Nivolumab Sunitinib Soft Tissue Sarcoma|Bone Sarcoma Phase I| Phase II Europe 2017 No
  1. Note: Nivolumab and pembrolizumab are PD-1 antibodies while camrelizumab is PD-L1 antibody